GlassScriptPhysician profile
Jason Lopez
NPI 1659802916
$5,983.33
in general payments reported to CMS, 2019-2025
17 companies · $3,951 in 2025
The $3,951 reported for 2025 was more than what 94% of Psychiatry providers received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $491 · 2020: $248 · 2021: $104 · 2022: $386 · 2023: $254 · 2024: $549 · 2025: $3,951.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Debt Forgiveness: $3,720 · Food and Beverage: $922 · Education: $111.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Debt Forgiveness | $3,720.00 |
| Food and Beverage | $922.25 |
| Education | $111.49 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Neuronetics, INC. | $3,735.81 | 2022-2025 | Neurostar Tms Therapy System |
| Allergan, INC. | $491.64 | 2019-2020 | |
| Teva Pharmaceuticals USA, INC. | $413.33 | 2022-2025 | Austedo Xr, Austedo, Austedo Xr |
| Axsome Therapeutics, INC. | $249.55 | 2023-2025 | Auvelity |
| Neurocrine Biosciences, INC. | $220.51 | 2019-2021 | |
| Otsuka America Pharmaceutical, INC. | $206.26 | 2021-2024 | Rexulti, Abilify Asimtufii, Abilify Maintena |
| Alkermes, INC. | $132.96 | 2021-2024 | Aristada, Lybalvi |
| Janssen Pharmaceuticals, INC | $132.33 | 2021-2025 | Invega Sustenna |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $131.69 | 2022-2025 | Caplyta |
| Vanda Pharmaceuticals INC. | $70.04 | 2020-2024 | Fanapt, Hetlioz |
| Lundbeck LLC | $45.41 | 2022 | |
| Ironshore Pharmaceuticals INC. | $36.29 | 2022-2024 | |
| Tempus Ai, INC | $28.71 | 2024 | |
| Almatica Pharma LLC | $27.80 | 2024 | Loreev Xr |
| E.R. Squibb & Sons, L.L.C. | $26.14 | 2024 | Cobenfy |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $17.53 | 2022 | |
| Indivior INC. | $17.33 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jason Lopez listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.